Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001231

Drug Information
NameOxybuprocaine
SynonymsNCGC00016667-01; Oxibuprokain; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; diethylaminoethyl-4-amino-3-butoxybenzoate; 4-Amino-3-butoxybenzoic acid 2-diethylaminoethyl ester; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 99-43-4; Monofree oxybuprocaine; Prestwick2_000057; Prestwick1_000057; BRD-K04185004-003-03-6; MLS001332643; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; Oxybuprocainum [INN-Latin]; Benoxinate; Prestwick3_000057; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; Novesinol; butoxyprocaine; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; AC1L1ILS; BPBio1_000235; Oxybuprocainum; S 749; oxybuprocaine hydrochloride; Benoxinate hydrochloride; Oxybuprocaine; NCGC00016667-02; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Oxibuprocainum; Oxybuprocaine (INN); Novescine; SPBio_002134; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]; Oxybucaine; CHEBI:309594; Oxybuprocaine HCL; CAS-5987-82-6; CID4633; LS-35639; SBB065174; 13718-13-3 (hydrochloride); MLS001332644; Conjucain; DB00892; Oxibuprocaina; UNII-AXQ0JYM303; Butoxyaminobenzoyldiethylaminoethanol; Prestwick0_000057; STK520615; CHEMBL1200; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; D08319; 5987-82-6 (mono-hydrochloride); Oxybuprocaine [INN:BAN]; Prescaina; SMR000857098; Oxyriprocaine; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; BRN 2288926; Oxibuprocaina [INN-Spanish]; 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; I01-7205; Monofree oxybuprocaine (TN); Benoxil; BSPBio_000213; Dorsacain
Trade NameNovesine; Novesin
CompanyNorvatis Phamaceuticals Corporation
IndicationAnesthetic
[ICD9: 338   ICD10: R52]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-1
9(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
InChIKeyCMHHMUWAYWTMGS-UHFFFAOYSA-N
Canonical SMILESCCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N    
Therapeutic ClassAnesthetics
CAS NumberCAS 99-43-4
FormulaC17H28N2O3
PubChem Compound IDCID 4633.
PubChem Substance IDSID 150504.
SuperDrug ATC IDD04AB03; S01HA02
SuperDrug CAS ID000099434;
TargetSodium channelBlocker[2]
Ref 1Drug information of Oxybuprocaine, 2008 To Reference
Ref 2Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. Epub 2009 Mar 11. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543